Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (PDF)

Active thyroid eye disease (TED), a progressive, autoimmune condition, produces retro-orbital inflammation/tissue expansion. Patients present with ocular pain, redness, and swelling. Retro-orbital fat/muscle expansion produces subsequent proptosis, diplopia, and strabismus. These manifestations can persist after inflammation is no longer evident. A phase 3 placebo-controlled trial recently confirmed that teprotumumab, an IGF-1R inhibitory antibody, significantly reduced TED-associated proptosis and improved other outcomes.[1] Key TED outcomes (proptosis [mm], subjective Bahn/Gorman diplopia grade, and GO-QOL) from the teprotumumab phase 2 and 3 trials are reported here.[1,2]